PetMed Express Posts Sharp Revenue Decline in Fiscal 2026

Benzinga reported Tuesday that PetMed Express revenue decline reached 21.1% across the full fiscal year 2026. The online pet pharmacy, trading on NASDAQ as PETS, also saw fourth-quarter net sales fall 15.6% year over year. That quarterly figure, however, was meaningfully smaller than earlier periods, suggesting the company’s slide may be stabilising.

Margins Recover Even as Sales Fall

Despite continued top-line pressure, PetMed Express delivered a notable improvement in profitability. Gross profit margin widened to 32.6% in Q4 2026, compared with 29.9% during the same quarter a year earlier. That expansion came even as the company absorbed a $26.7 million non-cash goodwill impairment charge. Management also recorded a $2.1 million inventory write-down and roughly $4.5 million in non-recurring costs tied to legal proceedings and severance payments.

Also Read: What Is a Goodwill Impairment and Why Does It Matter to Investors?

Technology Upgrades and Cost Cuts Drive Second-Half Momentum

The company pointed to a series of internal improvements as drivers of the better second-half showing. PetMed implemented a new enterprise resource planning system alongside upgraded call-centre technology. Both tools were credited with lifting customer experience scores and tightening operational efficiency. Cost reduction efforts ran in parallel, helping to partially offset the revenue headwinds hitting the broader pet-services sector.

Background: A Company Under Persistent Pressure

PetMed Express has faced mounting competition from large-box retailers and integrated veterinary platforms over recent years. The company’s revenue had been declining well before fiscal 2026 began, reflecting a structural shift in how pet owners purchase medications and wellness products. The goodwill impairment recorded this year acknowledges that the value of prior acquisitions no longer holds at original carrying amounts, a reflection of that sustained strain.

Also Read: PetMed Express Investor Relations Page

Management Opts to Go It Alone

One of the more consequential disclosures from the earnings call was PetMed’s decision to remain an independent company. Management said the board reviewed unsolicited acquisition proposals and ultimately declined them. Instead, leadership outlined plans to pursue business-to-business partnerships and expand its market reach through new distribution channels. Website enhancements and user-experience upgrades are also scheduled to continue in the year ahead. The company framed independence as the best path to building long-term value for shareholders rather than accepting near-term premiums from outside buyers.

Read Next: What Slowing Pet-Sector Spending Means for Consumer Discretionary Stocks